Results 71 to 80 of about 53,199 (230)

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model

BMC Cancer, 2012
Background Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory.
Wang Cun, Gao Dongmei, Guo Kun, Kang Xiaonan, Jiang Kai, Sun Chun, Li Yan, Sun Lu, Shu Hong, Jin Guangzhi, Sun Haiyan, Wu Weizhong, Liu Yinkun   +12 more
doaj   +1 more source

Successful Bortezomib-Lenalidomide-Dexamethasone Therapy in a 72-Year-Old Patient With Sporadic Late-Onset Nemaline Myopathy Associated With Monoclonal Gammopathy of Muscle Significance. [PDF]

Muscle Nerve
Muscle &Nerve, Volume 74, Issue 3, Page 756-758, September 2026.
Komatsu H, Komaki S, Maeda M, Kubota A, Yuasa M, Kurokawa M, Morishima R, Uruha S, Uruha A, Nishino I, Hamada M, Toda T, Satake W.   +12 more
europepmc   +2 more sources

Extramedullary Plasmacytoma of Base of Tongue: A Systematic Review

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Identifying extramedullary plasmacytoma originating from the base‐of‐tongue, in order to evaluate its prevalence, characteristics, management, and treatment within the broader spectrum of head and neck extramedullary plasmacytoma.
Ori Cohen Michael, Ameen Biadsee, Firas Kassem, Matan Katz, Osnat Jarchowsky‐Dolberg, Benny Nageris, Tomer Boldes   +6 more
wiley   +1 more source

Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States.

PLoS ONE, 2016
This study is a pharmacoepidemiologic description of pediatric bortezomib use. Exposure was identified through billing codes in patients admitted to US children's hospitals that participated with the Pediatric Health Information System between 2004 and ...
Amanda M DiNofia, Elizabeth Salazar, Alix E Seif, Yimei Li, Yuan-Shung Vera Huang, Rochelle Bagatell, Brian T Fisher, Richard Aplenc   +7 more
doaj   +1 more source

Real‐World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This retrospective case series evaluated all patients treated with daratumumab between 2018 and 2023 across two regional hospitals in Australia. Fifty‐two patients were included with a median age of 74. Median progression‐free survival (PFS) was 13 months and overall survival (OS) was 27 months, with an overall response rate was 35%.
Benjamin Reardon, Ian Kerridge, Tasman Armytage   +2 more
wiley   +1 more source

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Haematologica, 2015
Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome.
Marianne Kraus, Juergen Bader, Paul P. Geurink, Emily S. Weyburne, Anne C. Mirabella, Tobias Silzle, Tamer B. Shabaneh, Wouter A. van der Linden, Gerjan de Bruin, Sarah R. Haile, Eva van Rooden, Christina Appenzeller, Nan Li, Alexei F. Kisselev, Herman Overkleeft, Christoph Driessen   +15 more
doaj   +1 more source

Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma

British Journal of Haematology, EarlyView.
In patients with lenalidomide‐refractory multiple myeloma from the BOSTON trial subgroup analysis,1 selinexor (SEL) dose reduction versus full dosing substantially improved efficacy outcomes, including higher overall response rate (74.3% vs. 55.6%), deeper responses (≥ very good partial response: 48.6% vs.
Muhamed Baljevic
wiley   +1 more source

Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria

Journal of Global Oncology, 2017
Purpose: Novel therapy has dramatically changed the outcome of patients with myeloma. Current National Comprehensive Cancer Network guidelines give bortezomib-based combinations a central role in the management of multiple myeloma (MM).
Kaladada I. Korubo, Anazoeze J. Madu, Helen C. Okoye, Benedict Nwogoh   +3 more
doaj   +1 more source

Bortezomib in the management of multiple myeloma

, 2009
Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, Robert Schlossman, Dharminder Chauhan, Nikhil Munshi, Irene Ghobrial, Nicole Carreau, Kenneth C Anderson, Paul G RichardsonDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston ...
Teru Hideshima, et al, Jacob P Laubach, Constantine S Mitsiades   +3 more
core  

CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib

British Journal of Haematology, EarlyView.
Summary Cluster of differentiation 47 (CD47), a ‘don't eat me’ immune checkpoint receptor, is frequently overexpressed on multiple myeloma (MM) cells and contributes to immune evasion. While its immune regulatory function is well established, the intrinsic oncogenic role of CD47 remains poorly understood.
Omar Faruq, Deepak Iyer, Patrick Wang, Mariusz Shrestha, Cuihong Wei, Aaron D. Schimmer, Hong Chang   +6 more
wiley   +1 more source